Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Publikáció
Genomic landscape of ERBB3 alterations in metastatic solid tumours: a real-world data analysis.
2026. nov. 2.· ESMO open· PUBMED
Publikáció
Identification of biomarkers to guide treatment strategies toward precision medicine in hepatocellular carcinoma: Editorial on "ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling".
2026. okt. 29.· Clinical and molecular hepatology· PUBMED
Publikáció
68Ga/177Lu-Labeled Seribantumab as the Theranostic Drugs in Treating HER3-Positive Hepatocellular Carcinoma.
2026. okt. 24.· Drug design, development and therapy· PUBMED
Publikáció
A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study.
2026. okt. 12.· Future oncology (London, England)· PUBMED
Publikáció
Expression of Concern for EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer.
2026. okt. 1.· The Journal of clinical investigation· PUBMED
Vizsgálat
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
2026. szept. 17.· PHASE1_PHASE2 · RECRUITING· CTGOV
Publikáció
Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.
2026. szept. 11.· Journal of gynecologic oncology· PUBMED
Publikáció
Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study.
2026. szept. 11.· Annals of oncology : official journal of the European Society for Medical Oncology· PUBMED
Publikáció
ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.
2026. szept. 10.· Cell reports· PUBMED
Publikáció
Clinicopathological and Prognostic Significance of TROP2 and HER3 Expression in Early-Stage Cervical Carcinoma.
2026. szept. 7.· Diagnostics (Basel, Switzerland)· PUBMED
Publikáció
PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer.
2026. aug. 21.· Cell reports. Medicine· PUBMED
Publikáció
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.
2026. júl. 24.· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publikáció
NRG1 fusions in non-small cell lung cancer: biology, diagnostics, and emerging HER2/HER3 therapies-a narrative review.
2026. júl. 14.· Translational lung cancer research· PUBMED
Publikáció
COLEC12high tumor-associated macrophages: A novel paracrine axis driving lenvatinib resistance in hepatocellular carcinoma: Editorial on "COLEC12high tumor-associated macrophages orchestrate lenvatinib resistance and cancer stemness in hepatocellular carcinoma via paracrine NRG1-HER2/HER3 signaling".
2026. júl. 1.· Clinical and molecular hepatology· PUBMED
Publikáció
ERBB3 Promotes Malignant Behaviors of Endometrial Cancer Cells with Involvement of the Ras-ERK/MAPK Signaling Pathway.
2026. máj. 28.· Cancers· PUBMED
Publikáció
Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond.
2026. ápr. 21.· Antibody therapeutics· PUBMED
Publikáció
ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage.
2026. ápr. 15.· British journal of cancer· PUBMED
Publikáció
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer.
2026. ápr. 7.· The Journal of clinical investigation· PUBMED
Publikáció
Lung Adenocarcinoma Developing Pleomorphic Carcinoma With ERBB3 Amplification After Acquired Resistance to Sotorasib: A Case Report.
2026. márc. 28.· JTO clinical and research reports· PUBMED
Publikáció
[Expression of NF-κB, EGFR, and HER3 in castration-resistant prostate adenocarcinoma: a clinical and molecular study of 88 Moroccan patients].
2026. márc. 26.· The Pan African medical journal· PUBMED
Publikáció
Oligodendrocyte-secreted ERBB3 Mediates the Competitive Uptake of Copper Ions by Tumor Cells to Promote Brain Metastasis in Lung Cancer.
2026. márc. 25.· International journal of biological sciences· PUBMED
Publikáció
An integrated microfluidic system for automatic and self-validated analysis of cervical extracellular vesicle markers PD-L1 and ERBB3.
2026. márc. 16.· Analytical sciences : the international journal of the Japan Society for Analytical Chemistry· PUBMED
Publikáció
The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study.
2026. márc. 13.· Medicina (Kaunas, Lithuania)· PUBMED
Publikáció
HER3 and FOLR1 Expression as Actionable Targets in High-Grade Serous Ovarian Carcinoma: Prognostic and Therapeutic Implications.
2026. márc. 5.· Medicina (Kaunas, Lithuania)· PUBMED
Publikáció
Non-HLA Risk Loci ERBB3/IKZF4 and ERBB2/IKZF3/GSDMB/ORMDL3 Interact to Influence Progression of Autoimmunity in Relatives of T1D Patients.
2026. márc. 1.· Diabetes/metabolism research and reviews· PUBMED
Publikáció
The Impact of HER3 Dynamics Altered by HER3-DXd Alone and in Combination with Driver Oncogene Inhibitors on HER3-DXd Efficacy.
2026. febr. 17.· International journal of molecular sciences· PUBMED
Vizsgálat
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
2026. jan. 31.· PHASE2 · RECRUITING· CTGOV
Publikáció
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.
2026. jan. 27.· Annals of oncology : official journal of the European Society for Medical Oncology· PUBMED
Publikáció
A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC.
2026. jan. 27.· Cellular oncology (Dordrecht, Netherlands)· PUBMED
Publikáció
Pattern of HER2 and HER3 Overexpression in Patients with Pancreatic Ductal Adenocarcinoma.
2026. jan. 24.· Medicina (Kaunas, Lithuania)· PUBMED